BioNTech SE (BNTX)

87,21 +0,50 (+0,58%) Al cierre: 04:00PM EDT

BioNTech SE

An der Goldgrube 12
Mainz 55131
Germany
49 6131 9084 0
https://www.biontech.de

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 6133

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Ugur Sahin M.D.	Co-Founder, CEO & Chair of the Management Board	1,24M	N/A	1965
Dr. Ozlem Tureci M.D.	Co-Founder, Chief Medical Officer & Member of Management Board	814,23k	N/A	1967
Mr. Jens H. Holstein	CFO & Member of Management Board	1,43M	N/A	1963
Dr. Sierk Poetting Ph.D.	MD, COO & Member of Management Board	836,75k	N/A	1973
Mr. Ryan Richardson	Chief Strategy Officer, MD & Member of Management Board	1,03M	N/A	1979
Mr. Sean Marett	Chief Business Officer, Chief Commercial Officer & Member of Management Board	807,79k	N/A	1965
Dr. James Timothy Patrick Ryan Ph.D.	Chief Legal Officer & Member of the Management Board	605,04k	N/A	1975
Mr. Zach Taylor	Senior Vice President of Corporate Development & Strategy	N/A	N/A	N/A
Dr. Katalin Kariko Ph.D.	Senior VP & External Consultant for RNA Protein Replacement Therapies	N/A	N/A	N/A
Dr. Oliver Henning Ph.D.	Senior Vice President of Operations	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Gobierno corporativo

El ISS Governance QualityScore de BioNTech SE, a día 1 de abril de 2024, es 5. Las puntuaciones base son Auditoría: 6; Tablero: 3; Derechos de los accionistas: 1; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.